Cost-Effectiveness of Targeted Prophylaxis among Allogenic Stem Cell Transplant Recipients.
antibiotic prophylaxis
bloodstream infections
cost-effectiveness analysis
multi-drug resistant infections
onco-hematologic transplant
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
21 Mar 2023
21 Mar 2023
Historique:
received:
05
02
2023
revised:
15
03
2023
accepted:
17
03
2023
medline:
30
3
2023
entrez:
29
3
2023
pubmed:
30
3
2023
Statut:
epublish
Résumé
Bloodstream infections (BSI) are life-threatening complications for onco-hematologic patients. Fluoroquinolones prophylaxis (FQP) was recommended for patients with neutropenia. Later, it was correlated with increased resistance rates among this population and its role became debated. While the role of FQ prophylaxis is still being studied, its cost-effectiveness is also unknown. The objective of this study was to evaluate the costs and effects associated with two alternative strategies (FQP vs. no prophylaxis) for patients with hematological malignancies undergoing allogenic stem cell transplant (HSCT). A decision-tree model was built integrating retrospectively collected data from a single transplant center, part of a tertiary teaching hospital in Northern Italy. Probabilities, costs and effects were considered in the assessment of the two alternative strategies. Probabilities of colonization, BSIs, extended-spectrum beta lactamase (ESBL) and
Identifiants
pubmed: 36986564
pii: ph16030466
doi: 10.3390/ph16030466
pmc: PMC10053123
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Am J Infect Control. 2005 Aug;33(6):326-32
pubmed: 16061138
Arch Intern Med. 2011 Sep 12;171(16):1502-3
pubmed: 21911638
J Antimicrob Chemother. 2011 Mar;66(3):657-63
pubmed: 21193475
Clin Infect Dis. 2001 Apr 15;32(8):1162-71
pubmed: 11283805
Clin Infect Dis. 2022 Aug 24;75(1):178-179
pubmed: 34864924
JAMA Oncol. 2021 Nov 01;7(11):1626-1634
pubmed: 34499078
Clin Microbiol Infect. 1996 Mar;1(3):160-167
pubmed: 11866751
Haematologica. 2013 Dec;98(12):1821-5
pubmed: 24323982
Eur J Clin Microbiol Infect Dis. 2004 Mar;23(3):163-7
pubmed: 14986159
Antibiotics (Basel). 2022 May 20;11(5):
pubmed: 35625339
JAMA. 2016 Sep 20;316(11):1193-1204
pubmed: 27654605
J Chemother. 2005 Jun;17(3):251-7
pubmed: 16038517
Clin Infect Dis. 2002 Mar 15;34(6):730-51
pubmed: 11850858
J Hosp Infect. 2021 Jul;113:164-171
pubmed: 33940090
Dis Mon. 2020 Jun;66(6):100971
pubmed: 32201008
Cent Eur J Oper Res. 2018;26(1):135-159
pubmed: 29375266
Ann Intern Med. 2005 Jun 21;142(12 Pt 1):979-95
pubmed: 15968013
Int J Antimicrob Agents. 2008 Nov;32 Suppl 1:S30-3
pubmed: 18778919
Intern Med J. 2011 Jan;41(1b):102-9
pubmed: 21272174
J Infect. 2018 Jan;76(1):20-37
pubmed: 29079323
J Infect Dev Ctries. 2018 Jun 30;12(6):442-447
pubmed: 31940295
Biol Blood Marrow Transplant. 2009 Jan;15(1):47-53
pubmed: 19135942
J Infect. 2018 Jul;77(1):1-8
pubmed: 29746948
Pediatr Blood Cancer. 2020 Oct;67(10):e28469
pubmed: 32710709
Cancer. 2006 May 15;106(10):2258-66
pubmed: 16575919
N Engl J Med. 2005 Sep 8;353(10):988-98
pubmed: 16148284
N Engl J Med. 2005 Sep 8;353(10):977-87
pubmed: 16148283
J Clin Microbiol. 2010 May;48(5):1726-31
pubmed: 20181897
Clin Microbiol Infect. 2012 May;18(5):413-31
pubmed: 22507109